
KEY PRODUCTS
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : LIR Life Sciences
Deal Size : Undisclosed
Deal Type : Agreement
LIR Life Partners Neuland Labs for Transdermal GLP-1/GIP Peptides
Details : The agreement will support the clinical development of an undisclosed peptide targeting GLP-1/GIP for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
January 18, 2026
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : LIR Life Sciences
Deal Size : Undisclosed
Deal Type : Agreement



Neuland Laboratories- A dedicated 100% API provider.